MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414801 | Name: Tigapotide triflutate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tigapotide triflutate is a synthetic peptide corresponding to amino acids 31-45 of PSP94 (prostate secretory protein) that inhibits matrix metalloproteinase-9 secretion.

Chemical Structure

Tigapotide triflutate
Tigapotide triflutate
CAS#848084-84-4 (triflutate)

Theoretical Analysis

MedKoo Cat#: 414801

Name: Tigapotide triflutate

CAS#: 848084-84-4 (triflutate)

Chemical Formula: C84H120F3N21O36S3

Exact Mass:

Molecular Weight: 2153.17

Elemental Analysis: C, 46.86; H, 5.62; F, 2.65; N, 13.66; O, 26.75; S, 4.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
848084-84-4 (triflutate); 848084-83-3 (free base)
Synonym
Tigapotide triflutate; PCK 3145; PCK-3145; PCK3145
IUPAC/Chemical Name
(2S,5S,8S,11R,14S,17R,20S,23S,26R,29S,32S,35S,38S,41S,44S)-41-((1H-indol-3-yl)methyl)-11,17,26-tris(((acetamidomethyl)thio)methyl)-44-amino-29-(2-amino-2-oxoethyl)-38-(3-amino-3-oxopropyl)-5,23-bis(2-carboxyethyl)-32-(carboxymethyl)-8-(4-hydroxybenzyl)-2,14,20,35-tetrakis((R)-1-hydroxyethyl)-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecaazaheptatetracontanedioic acid compound with 2,2,2-trifluoroacetic acid (1:1)
InChi Key
PNJSAKBBGRRTHL-RBUYSXEJSA-N
InChi Code
InChI=1S/C82H119N21O34S3.C2HF3O2/c1-35(104)64(100-69(123)48(17-20-58(84)112)90-73(127)52(93-68(122)46(83)16-21-60(114)115)25-43-28-86-47-11-9-8-10-45(43)47)79(133)96-54(27-63(120)121)75(129)95-53(26-59(85)113)74(128)97-55(29-138-32-87-39(5)108)76(130)92-49(18-22-61(116)117)70(124)101-65(36(2)105)80(134)99-57(31-140-34-89-41(7)110)78(132)102-66(37(3)106)81(135)98-56(30-139-33-88-40(6)109)77(131)94-51(24-42-12-14-44(111)15-13-42)72(126)91-50(19-23-62(118)119)71(125)103-67(38(4)107)82(136)137;3-2(4,5)1(6)7/h8-15,28,35-38,46,48-57,64-67,86,104-107,111H,16-27,29-34,83H2,1-7H3,(H2,84,112)(H2,85,113)(H,87,108)(H,88,109)(H,89,110)(H,90,127)(H,91,126)(H,92,130)(H,93,122)(H,94,131)(H,95,129)(H,96,133)(H,97,128)(H,98,135)(H,99,134)(H,100,123)(H,101,124)(H,102,132)(H,103,125)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,136,137);(H,6,7)/t35-,36-,37-,38-,46+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,64+,65+,66+,67+;/m1./s1
SMILES Code
C[C@H]([C@@H](C(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@H](CCC(O)=O)N)=O)Cc(c[nH]1)c2c1cccc2)=O)CCC(N)=O)=O)=O)CC(O)=O)=O)CC(N)=O)=O)CSCNC(C)=O)=O)CCC(O)=O)=O)=O)CSCNC(C)=O)=O)=O)CSCNC(C)=O)=O)Cc3ccc(O)cc3)=O)CCC(O)=O)=O)O.OC(C(F)(F)F)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,153.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs. 2005 Nov;16(10):1045-51. doi: 10.1097/00001813-200511000-00002. PMID: 16222145. 2: Danika C, El Mubarak MA, Leontari I, Sivolapenko GB. Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice. Anal Biochem. 2019 Jan 1;564-565:72-79. doi: 10.1016/j.ab.2018.10.005. Epub 2018 Oct 17. PMID: 30339813. 3: Kostopoulos A, Papageorgiou E, Koutsilieris M, Sivolapenko G. PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells. Anticancer Res. 2015 Mar;35(3):1377-84. PMID: 25750288. 4: Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ. PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer. Oncogene. 2014 Nov 6;33(45):5288-94. doi: 10.1038/onc.2013.466. Epub 2013 Nov 4. PMID: 24186202. 5: El Mubarak MA, Leontari I, Danika C, Katsila T, Sivolapenko G. Development and validation of a UHPLC-UV method for the determination of a prostate secretory protein 94-derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma. Biomed Chromatogr. 2016 Sep;30(9):1476-80. doi: 10.1002/bmc.3708. Epub 2016 Mar 21. PMID: 26892539. 6: Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun. 2006 Jul 21;346(1):358-66. doi: 10.1016/j.bbrc.2006.05.139. Epub 2006 Jun 2. PMID: 16759641. 7: Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis. 2005;22(5):429-39. doi: 10.1007/s10585-005-2669-1. PMID: 16283486. 8: Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Inhibition of MMP-9 secretion by the anti- metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs. 2006 Apr;17(4):429-38. doi: 10.1097/01.cad.0000203388.68034.06. PMID: 16550001. 9: Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer. 2006 May 1;118(9):2350-8. doi: 10.1002/ijc.21615. PMID: 16331603. 10: Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer. 2005 Sep;4(2):91-9. doi: 10.3816/cgc.2005.n.016. PMID: 16197609.